Emerging technologies / FDA · August 19, 2026

A robot draws the blood, a phlebotomist remains in charge

Vitestro's Aletta is FDA-authorized for outpatient adult blood draws under trained phlebotomist oversight. Authorization is not proof of widespread deployment.

FDA · August 19, 2026 · FDA-authorized; rollout stage · Dr. Mohan's take

The pathologist's read

Blood collection is easy to overlook until the draw is difficult, delayed or repeated. Aletta pairs imaging and robotics to find a vein, place the needle and fill tubes; a trained phlebotomist initiates and oversees the process and checks tube order and fill. The FDA's De Novo authorization is a real regulatory milestone, but a permission to market is not proof of widespread deployment. Its clinical comparison applies when the device proceeds with a stick. The most useful question now is how this works in ordinary collection rooms across patients, with safety, specimen quality, patient experience and staffing measured honestly. A tool for consistency and capacity, not a replacement for laboratory judgment.

Read the FDA announcement →

FDA De Novo DEN250046 authorizes adults in outpatient settings, under a trained phlebotomist who can oversee up to three devices. FDA comparisons count successful draws when the device proceeds with a stick. U.S. rollout is still phasing in. Not medical advice.

← More from Doctor's Doc MD